Key result
A combined pentavalent vaccine with acellular pertussis was at least as immunogenic as the whole-cell pertussis combination, with a better safety profile and higher Hib booster response.
Why the study?
Does a combined acellular pertussis pentavalent vaccine improve safety and immunogenicity compared to a whole cell pertussis pentavalent vaccine in healthy infants?
RCT (n=201)
Open-label
randomized
Does a combined acellular pertussis pentavalent vaccine improve safety and immunogenicity compared to a whole cell pertussis pentavalent vaccine in healthy infants?
A combined pentavalent vaccine containing acellular pertussis is at least as immunogenic as one containing whole cell pertussis, with a significantly better safety profile in infants.
Answers are grounded in this paper and cite their sources.
Supports acellular pertussis pentavalent vaccines for infant schedules; confirms noninferior immunogenicity with superior safety in RCT evidence.
BACKGROUND: We compared the safety and immunogenicity of two combined diphtheria-tetanus-pertussis-inactivated poliovirus vaccines containing either acellular (Pa, SmithKline Beecham Biologicals) or whole cell (Pw, Pasteur Merieux Connaught) pertussis components, mixed with a Haemophilus influenzae type b polysaccharide polyribosylribitol phosphate-tetanus conjugate vaccine in an open, randomized study in healthy infants. DESIGN: The combined vaccines were given at 2, 4, 6 and 12 months of age, and serum samples were obtained at ages 2, 6, 7, 12 and 13 months. Adverse events were obtained by diary cards. RESULTS: The Pa group (n = 101) had a clearly lower incidence of both local and systemic adverse events than the Pw group (n = 100). Immunogenicity was comparable for the diphtheria and tetanus components, but significantly superior for pertussis toxin, filamentous hemagglutinin, pertactin and polioviruses 1, 2 and 3 in the Pa group. Both groups had an appropriate response with regard to H. influenzae type b polysaccharide polyribosylribitol phosphate, but the dynamics of the response were significantly different: geometric mean concentrations (micrograms per ml) after the second, third and booster doses were 1.27, 5.06 and 23.12 in the Pa group and 2.72, 6.66 and 13.59 in the Pw group, respectively (P = 0.0002 after second dose; P = 0.0005 after booster). CONCLUSION: The presently studied diphtheria, tetanus, acellular pertussis-H. influenzae b vaccine conjugated to tetanus toxoid combination was at least as immunogenic as the diphtheria, tetanus, whole cell pertussis-H. influenzae b vaccine conjugated to tetanus toxoid combination, with a significantly better safety profile. This is of obvious importance in countries where inactivated poliovirus vaccine is part of the routine infant immunization programs.
No takes yet. Share an insight, caveat, or question.
Dagan et al. (1997) conducted an RCT in Healthy infants requiring immunization (n=201). Combined pentavalent vaccine with acellular pertussis (Pa) vs. Combined pentavalent vaccine with whole cell pertussis (Pw) was evaluated on Safety and immunogenicity. A combined pentavalent vaccine with acellular pertussis was at least as immunogenic as the whole-cell pertussis combination, with a better safety profile and higher Hib booster response.
Synapse has enriched 10 related papers. Consider them for comparative context: